These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 5040916

  • 1. Effect of L-dopa on plasma free fatty acids and plasma glucose.
    Rivera-Calimlim L, Bianchine JR.
    Metabolism; 1972 Jul; 21(7):611-7. PubMed ID: 5040916
    [No Abstract] [Full Text] [Related]

  • 2. Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism.
    Sirtori CR, Bolme P, Azarnoff DL.
    N Engl J Med; 1972 Oct 12; 287(15):729-33. PubMed ID: 5056733
    [No Abstract] [Full Text] [Related]

  • 3. L-dopa level in plasma, primary condition for the kinetic effect.
    Birkmayer W, Danielcyk W, Neumayer E, Riederer P.
    J Neural Transm; 1973 Oct 12; 34(2):133-43. PubMed ID: 4722571
    [No Abstract] [Full Text] [Related]

  • 4. Amantadine enhancement of L-DOPA induced growth hormone stimulation.
    Massara F, Camanni F, Molinatti GM.
    Horm Metab Res; 1973 Nov 12; 5(6):454-6. PubMed ID: 4767002
    [No Abstract] [Full Text] [Related]

  • 5. Stimulation of human-growth-hormone secretion by L-dopa.
    Boyd AE, Lebovitz HE, Pfeiffer JB.
    N Engl J Med; 1970 Dec 24; 283(26):1425-9. PubMed ID: 5481776
    [No Abstract] [Full Text] [Related]

  • 6. Plasma growth hormone and insulin response to levodopa and amantadine.
    Kytömäki O, Nousiainen R, Pekkarinen A, Rinne UK, Viljanen M.
    J Neural Transm; 1973 Dec 24; 34(2):145-51. PubMed ID: 4722572
    [No Abstract] [Full Text] [Related]

  • 7. [Effect of L-dopa on pituitary hormones and on carbohydrate and fat metabolism in normal persons and in patients with Parkinsonism].
    Geser CA, Müller-Hess R, Dufresne JJ, Felber JP, Vannotti A.
    Schweiz Med Wochenschr; 1973 May 12; 103(19):690-7. PubMed ID: 4703913
    [No Abstract] [Full Text] [Related]

  • 8. DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with Parkinson's disease before and during treatment with L-DOPA.
    Hare TA, Beasley BL, Chambers RA, Boehme DH, Vogel WH.
    Clin Chim Acta; 1973 May 18; 45(3):273-80. PubMed ID: 4708057
    [No Abstract] [Full Text] [Related]

  • 9. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
    Imai K, Sugiura M, Kubo H, Tamura Z, Oya K.
    Chem Pharm Bull (Tokyo); 1972 Apr 18; 20(4):759-64. PubMed ID: 5045616
    [No Abstract] [Full Text] [Related]

  • 10. The effect of L-dopa on plasma growth hormone, insulin, and thyroxine.
    Kansal PC, Buse J, Talbert OR, Buse MG.
    J Clin Endocrinol Metab; 1972 Jan 18; 34(1):99-105. PubMed ID: 5061778
    [No Abstract] [Full Text] [Related]

  • 11. [Effect of L-dopa on pituitary TSH and GH secretion in Parkinson's disease].
    Sakoda M, Kusaka T, Baba S, Shirakata S.
    Nihon Naibunpi Gakkai Zasshi; 1972 Jul 20; 48(4):241-4. PubMed ID: 5066290
    [No Abstract] [Full Text] [Related]

  • 12. Effects of L-dopa on plasma growth hormones and insulin.
    Kytomaki O, Nousiainen R, Pekkarinen A, Rinne U, Siirtola T, Sonninen V, Viljanen M.
    Acta Neurol Scand Suppl; 1972 Jul 20; 51():125-6. PubMed ID: 4514338
    [No Abstract] [Full Text] [Related]

  • 13. Effect of L-dopa administration on growth hormone secretion in normal subjects and Parkinsonian patients.
    Cavagnini F, Peracchi M, Scotti G, Raggi U, Pontiroli AE, Bana R.
    J Endocrinol; 1972 Sep 20; 54(3):425-33. PubMed ID: 5071365
    [No Abstract] [Full Text] [Related]

  • 14. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease.
    Hare TA, Vanna S, Beasley B, Chambers R, Vogel WH.
    J Lab Clin Med; 1971 Feb 20; 77(2):319-25. PubMed ID: 5540775
    [No Abstract] [Full Text] [Related]

  • 15. 3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease.
    Sharpless NS, Muenter MD, Tyce GM, Owen CA.
    Clin Chim Acta; 1972 Mar 20; 37():359-69. PubMed ID: 5022100
    [No Abstract] [Full Text] [Related]

  • 16. [Clinical effect of L-DOPA and electromyographic study of Parkinsonism].
    Sato G, Ito H, Handa Y, Takahashi I, Iijima K.
    No To Shinkei; 1971 Mar 20; 23(3):325-32. PubMed ID: 5107821
    [No Abstract] [Full Text] [Related]

  • 17. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.
    Muenter MD, Tyce GM.
    Mayo Clin Proc; 1971 Apr 20; 46(4):231-9. PubMed ID: 5573818
    [No Abstract] [Full Text] [Related]

  • 18. [Current treatment of Parkinson syndrome with L-dopa].
    Gerstendbrand F, Gründig E, Musiol A.
    Pol Tyg Lek; 1972 May 22; 27(21):798-800. PubMed ID: 4555002
    [No Abstract] [Full Text] [Related]

  • 19. Effect of intravenous infusion of L-DOPA on plasma growth hormone levels in man.
    Imura H, Nakai Y, Matsukura S, Matsuyama H.
    Horm Metab Res; 1973 Jan 22; 5(1):41-5. PubMed ID: 4706921
    [No Abstract] [Full Text] [Related]

  • 20. [L-dopa and Parkinson's disease].
    Barbeau A.
    Union Med Can; 1970 Dec 22; 99(12):2195-7. PubMed ID: 5488646
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.